Synaptogenix (NASDAQ:TAOX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Synaptogenix (NASDAQ:TAOX) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Synaptogenix Price Performance

NASDAQ:TAOX opened at $6.40 on Friday. Synaptogenix has a one year low of $1.84 and a one year high of $11.98. The business has a fifty day moving average of $7.26. The stock has a market cap of $45.63 million, a price-to-earnings ratio of -0.32 and a beta of 1.93.

Synaptogenix (NASDAQ:TAOX) last released its earnings results on Friday, November 14th. The company reported ($1.56) earnings per share for the quarter. The company had revenue of $2.41 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.